Gastrin I (1-14), human
CAS No. 100940-57-6
Gastrin I (1-14), human ( —— )
产品货号. M22724 CAS No. 100940-57-6
Gastrin I (1-14), human is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥4560 | 有现货 |
|
10MG | ¥6415 | 有现货 |
|
25MG | ¥9963 | 有现货 |
|
50MG | ¥13527 | 有现货 |
|
100MG | ¥18225 | 有现货 |
|
500MG | ¥36369 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Gastrin I (1-14), human
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Gastrin I (1-14), human is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion.
-
产品描述Gastrin I (1-14), human is 1-14 fragment of human gastrin I peptide. Gastrin I is an endogenous, gastrointestinal peptide hormone. Gastrin is the major hormonal regulator of gastric acid secretion.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域——
-
适应症——
化学信息
-
CAS Number100940-57-6
-
分子量1705.73
-
分子式C79H100N16O27
-
纯度>98% (HPLC)
-
溶解度H2O:Soluble
-
SMILESCSCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1cncn1)NC(=O)[C@H](CS)NC(=O)[C@H](Cc1cnc2ccccc12)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(C)=O)C(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Jordan PH Jr, et al. Physiology of gastrin. Am J Surg. 1969 Jun;117(6):822-30.
产品手册
关联产品
-
Sultiame
Sultiame is an inhibitor of carbonic anhydrase. Sultiame can be used in antiepileptic research.
-
AtPep3
AtPep3 is a hormone-like peptide that plays a role in the salinity stress tolerance of plants.
-
PF-00835231
PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively.PF-00835231 is the active compound of the first anti-3CLpro regimen in clinical trials.